Dr ZinX | July 10, 2020
Yonah S. Tehrani, MD on the potential benefit of the Dr ZinX Zinc + Hinokitiol combination: "The antiviral effects and benefits of Zinc and Hinokitiol may have a tremendous impact on affected individuals and health care systems worldwide."
Zinc is a mineral of critical importance to the proper functioning of the immune system in all age groups. Zinc deficiency may result in low resistance to viruses and bacteria. Studies dating back to 1974 have shown that zinc supplementation may contribute to faster recovery from viral illness by directly inhibiting viral replication at the protein level.
In order for Zinc to cross into our cells and operate a special transport system is required. This system includes zinc ionophores and zinc binding-proteins. The list of zinc ionophores is extensive and includes Hinokitiol, hydroxychloroquine, quercetin, epigallocatechin, pyrithione, zincophorin, and others.
Kedrion Biopharma | October 19, 2021
Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business.
Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for the treatment of all the clinical manifestations of Plasminogen Deficiency, which can lead to blindness, respiratory failure and other severe complications.
The company is now working toward a launch in the United States in early 2022.
"We are very pleased to have completed this important and strategic acquisition, which will bring badly needed therapies to patients who suffer from this rare disease,"
- Paolo Marcucci, Chairman of Kedrion Biopharma.
With the acquisition of Prometic BioTherapeutics Inc., Kedrion has finalized a series of transactions that began last June with the announcement that it was acquiring from the Nasdaq-quoted Liminal Biosciences Inc. the plasma purification plant at Laval in Quebec, and the license to distribute the new product in the United States.
"Ryplazim is very significant because it really allows us to fulfil our mission of putting patients first. This is the first drug to ever be approved by the FDA for the treatment of the rare Congenital Plasminogen Deficiency, Type 1, so we are very honored to help speed the product to market."
- Val Romberg, Kedrion's CEO
Telix Pharmaceuticals Limited | September 07, 2020
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate imaging is able to be an integral part of radiation treatment planning.